Navigation Links
Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results
Date:3/30/2008

e improvement of account receivables and lower consulting fees.

Aggregated research and development expenses for the fourth quarter of 2007 were $756,000, compared to $300,000 in the same period of 2006. The Company's net R&D expenses were $354,000 for the fourth quarter of 2007, compared to $162,000 in the same period of 2006. The R&D expenses recognized as a reduction to government grants were $755,726 in the fourth quarter of 2007, compared to $299,776 in the same period of 2006.

Operating income was $3.3 million for the fourth quarter of 2007, compared to $588,000 in the same period of 2006. The year-over-year increase in operating income reflected the significant increase in vaccine sales and the lower operating expenses.

Net income for the fourth quarter of 2007 was $2.0 million, or $0.05 per diluted share, compared to $181,000, or $0.005 per diluted share, in the same period of 2006. Net income for the fourth quarter of 2007 included $294,000 of interest and financing expenses, $42,000 of income taxes, and $965,000 of minority interest. Net income for the same period of 2006 included $95,000 of interest and financing expenses, $405,882 of income taxes, and $559,000 of minority interest.

Sales and Marketing

During the twelve months ended December 31, 2007, Sinovac sold total 5.12 million doses of Healive(R), up from 2.6 million doses in 2006. During the fourth quarter of 2007, Sinovac sold approximately 1.14 million doses of Healive(R), up from 1.07 million for the same period of 2006. During the fourth quarter, the higher sales reflected Sinovac's ongoing marketing activities. The initiation of the government paid market for the hepatitis A vaccine in China is expected to impact the seasonality of Healive(R) sales established in previous years.

For the twelve months ended December 31, 2007, Sinovac sold 1.59 million doses of Anflu(R), which accounted for 14.3% of full year sales. During the fourth quarter of 2007, Sin
'/>"/>

SOURCE Sinovac Biotech Co., Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Sinovac Announces Postponement of Annual General Meeting
2. Sinovac Requests Extension for Annual Shareholders Meeting
3. Sinovac Reports Top-Line Preliminary Phase II Results of Pandemic Influenza (H5N1) Whole Viron Vaccine
4. Sinovac Closes $9.75 Million Private Placement
5. Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
6. Sinovac Announces Adjournment of Annual General Meeting
7. Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2007 Financial Results
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. QMed, Inc. Reports July Medicare SNP Enrollments
10. Phlo Affiliate Reports Expanded Coverage to Oregon Border
11. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... DIEGO , March 3, 2015  Neurocrine Biosciences, ... Kevin Gorman , President and Chief Executive Officer ... Global Healthcare Conference in Miami.   The ... 10:15am ET (7:15am PT).  The presentation will be webcast ... http://www.neurocrine.com .   Listeners are encouraged ...
(Date:3/3/2015)... 2015 BlueInGreen announces ... international sales network. The business venture will bring ... Canada’s Atlantic Provinces, exclusively through Resource Systems. , ... of Canada’s premiere manufacturing representative firms, hosting a ... water and wastewater markets. More information on Resource ...
(Date:3/3/2015)... NEW YORK , March 3, 2015 ... that Jeffrey I.D. Lewis has joined the ... Practice, resident in the New York ... also handles trademark matters, as well as other intellectual ... registered patent attorney, Mr. Lewis represents both plaintiffs and ...
(Date:3/3/2015)... , March 3, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: ... the scientific journal, Expert Opinion on Biological Therapy ... Dr. Zhenggang Zhang , at the Henry Ford ... that Thymosin beta 4 (TB4) has the capacity to ... hours or more post-injury, leading to neurological recovery in ...
Breaking Biology Technology:BlueInGreen® Continues Canadian Expansion, Partners with Resource Systems Inc. 2Leading Patent Attorney Jeffrey Lewis Joins Fried Frank's Intellectual Property Litigation Practice 2Leading Patent Attorney Jeffrey Lewis Joins Fried Frank's Intellectual Property Litigation Practice 3Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 2Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 3
... Pa. and LYON, France, Aug. 1 Sanofi,Pasteur, ... vaccine (Fluzone(R), Influenza Virus Vaccine) in the United,States ... doses of influenza,vaccine began shipping this week following ... Food and Drug Administration (FDA) on,July 14, 2008., ...
... Due to its remarkable electronic properties, few layer graphene, ... for use in post-silicon devices that incorporate the quantum ... at the University of Pennsylvania have demonstrated a new ... crystallographic axes by using thermally activated nanoparticles, a technique ...
... THRM ), announced today that it will release ... 2008, after the market close on,Monday, August 11, 2008. ... on Tuesday, August 12, 2008, at 8:30 a.m. Eastern ... current corporate,developments. The dial-in number for the conference call ...
Cached Biology Technology:Sanofi Pasteur Shipping First Doses of Influenza Vaccine for the 2008-2009 Season 2Sanofi Pasteur Shipping First Doses of Influenza Vaccine for the 2008-2009 Season 3Sanofi Pasteur Shipping First Doses of Influenza Vaccine for the 2008-2009 Season 4Sanofi Pasteur Shipping First Doses of Influenza Vaccine for the 2008-2009 Season 5Penn scientists carve functional nanoribbons using super-heated, nano-sized particles of iron 2
(Date:2/5/2015)... , Jan. 26, 2015 NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing mobile ... website ( http://www.nxt-id.com/ ) as part of its 2015 ... The Company launched its new consumer website for Wocketwallet.com ... , CEO of NXT-ID said, "Our new corporate website ...
(Date:2/5/2015)... SAN FRANCISCO , January 28, 2015 ... Camera Market Analysis, Size And Segment Forecasts To 2020 ... The global IR camera market is expected to reach ... study by Grand View Research, Inc. IR cameras help ... injuries, and are expected to witness surging demand in ...
(Date:2/5/2015)... DUBLIN , Jan. 28, 2015 Research ... announced the addition of the "Global Biometrics ... Use, Regions and Countries " report to their ... market, Asia-Pacific is anticipated ... by 2015, owing to increasing government spending towards ...
Breaking Biology News(10 mins):NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3
... help to protect against some food allergies. Kefir, a traditional ... food, and is often used to wean babies, as it ... children under the age of three, with around 5-8% of ... the problematic food. , "Friendly" bacteria in kefir may play ...
... Small but remarkable fossils found in New Zealand will prompt a ... the so-called "land of birds" was once home to mammals as ... and a leg - belonged to a unique, mouse-sized land animal ... St Bathans fossil bed, in the Central Otago region of South ...
... Columbia University's Mailman School of Public Health, the Centers ... Research Center have discovered a key mechanism by which ... identification of an amino acid sequence in Filoviruses that ... described in the December 2006 issue of The FASEB ...
Cached Biology News:Friendly bacteria in alcoholic milkshake could fight food allergies 2Tiny bones rewrite textbooks 2Researchers discover key mechanism by which lethal viruses Ebola and Marburg cause disease 2
PlusOne EDTA, disodium salt, 100 g. Category: Electrophoresis Systems & Standards & Reagents, Electrophoresis Standards and Reagents, Buffers....
Normal human serum collected off the clot from healthy normal humans. Each donor unit is negative for anti-HIV 1&2, HIV-Ag, HCV, and HBsAg by FDA required tests...
sterile filtered, off the clot, all male donors, Total Protein: 4.5 to 8.5 g/dl...
Recombinant Mouse MMP-9, CF...
Biology Products: